A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1

Clinical Immunology

Volumn 153, Issue 1, 2014, Pages 220-227

  Breivik, Lars ^a   Oftedal, Bergithe E V ^a   Bøe Wolff, Anette S ^a   Bratland, Eirik ^a   Orlova, Elizaveta M ^c   Husebye, Eystein S ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c ENDOCRINOLOGY RESEARCH CENTRE   (Russian Federation)

Author keywords

Autoimmune polyendocrine syndrome I; Interferon alpha; Interferon omega; Neutralizing autoantibodies; Radioimmunoassay

Indexed keywords

ALPHA2A INTERFERON; AUTOANTIBODY; BETA INTERFERON; NEUTRALIZING ANTIBODY; OMEGA INTERFERON; REAGENT; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; ASSAY; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; BINDING ASSAY; BLOOD DONOR; CELL LINE; CONTROLLED STUDY; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PURIFICATION; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY; SERUM;

AUTOIMMUNE POLYENDOCRINE SYNDROME I; INTERFERON ALPHA; INTERFERON OMEGA; NEUTRALIZING AUTOANTIBODIES; RADIOIMMUNOASSAY;

ANTIBODIES, NEUTRALIZING; AUTOANTIBODIES; CELL LINE; HUMANS; IMMUNOASSAY; INTERFERON TYPE I; POLYENDOCRINOPATHIES, AUTOIMMUNE; SENSITIVITY AND SPECIFICITY;

EID: 84901316920     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.04.013     Document Type: Article

References (36)

1. Finnish-German A.C. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat. Genet. 1997, 17(4):399-403.
2. Nagamine K., Peterson P., Scott H.S., Kudoh J., Minoshima S., Heino M., Krohn K.J., Lalioti M.D., Mullis P.E., Antonarakis S.E., et al. Positional cloning of the APECED gene. Nat. Genet. 1997, 17(4):393-398.
3. Anderson M.S., Su M.A. Aire and T cell development. Curr. Opin. Immunol. 2011, 23(2):198-206.
4. Ahonen P., Myllarniemi S., Sipila I., Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N. Engl. J. Med. 1990, 322(26):1829-1836.
5. Neufeld M., Maclaren N.K., Blizzard R.M. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine 1981, 60(5):355-362.
6. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J. Clin. Endocrinol. Metab. 2006, 91(8):2843-2850.
7. Soderbergh A., Myhre A.G., Ekwall O., Gebre-Medhin G., Hedstrand H., Landgren E., Miettinen A., Eskelin P., Halonen M., Tuomi T., et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J. Clin. Endocrinol. Metab. 2004, 89(2):557-562.
8. Winqvist O., Gustafsson J., Rorsman F., Karlsson F.A., Kampe O. Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type I and Addison's disease. J. Clin. Invest. 1993, 92(5):2377-2385.
9. Alimohammadi M., Bjorklund P., Hallgren A., Pontynen N., Szinnai G., Shikama N., Keller M.P., Ekwall O., Kinkel S.A., Husebye E.S., et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N. Engl. J. Med. 2008, 358(10):1018-1028.
10. Meager A., Visvalingam K., Peterson P., Moll K., Murumagi A., Krohn K., Eskelin P., Perheentupa J., Husebye E., Kadota Y., et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006, 3(7):e289.
11. Oftedal B.E., Wolff A.S., Bratland E., Kampe O., Perheentupa J., Myhre A.G., Meager A., Purushothaman R., Ten S., Husebye E.S. Radioimmunoassay for autoantibodies against interferon ω its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin. Immunol. 2008, 129(1):163-169.
12. Puel A., Doffinger R., Natividad A., Chrabieh M., Barcenas-Morales G., Picard C., Cobat A., Ouachee-Chardin M., Toulon A., Bustamante J., et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 2010, 207(2):291-297.
13. Kisand K., Boe Wolff A.S., Podkrajsek K.T., Tserel L., Link M., Kisand K.V., Ersvaer E., Perheentupa J., Erichsen M.M., Bratanic N., et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 2010, 207(2):299-308.
14. Husebye E.S., Perheentupa J., Rautemaa R., Kampe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J. Intern. Med. 2009, 265(5):514-529.
15. Wolff A.S., Sarkadi A.K., Marodi L., Karner J., Orlova E., Oftedal B.E., Kisand K., Olah E., Meloni A., Myhre A.G., et al. Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. J. Clin. Immunol. 2013, 33(8):1341-1348.
16. Meager A., Wadhwa M., Dilger P., Bird C., Thorpe R., Newsom-Davis J., Willcox N. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin. Exp. Immunol. 2003, 132(1):128-136.
17. Zhang L., Barker J.M., Babu S., Su M., Stenerson M., Cheng M., Shum A., Zamir E., Badolato R., Law A., et al. A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin. Immunol. 2007, 125(2):131-137.
18. Wolff A.S., Erichsen M.M., Meager A., Magitta N.F., Myhre A.G., Bollerslev J., Fougner K.J., Lima K., Knappskog P.M., Husebye E.S. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J. Clin. Endocrinol. Metab. 2007, 92(2):595-603.
19. Orlova E.M., Bukina A.M., Kuznetsova E.S., Kareva M.A., Zakharova E.U., Peterkova V.A., Dedov I.I. Autoimmune polyglandular syndrome type 1 in Russian patients: clinical variants and autoimmune regulator mutations. Horm. Res. Paediatr. 2010, 73(6):449-457.
20. Wadhwa M., Subramanyam M., Goelz S., Goyal J., Jethwa V., Jones W., Files J.G., Kramer D., Bird C., Dilger P., et al. Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-beta. J. Interferon Cytokine Res. 2013, 33(11):660-671.
21. Prummer O., Streichan U., Heimpel H., Porzsolt F. Sensitive antiproliferative neutralization assay for the detection of neutralizing IFN-alpha and IFN-beta antibodies. J. Immunol. Methods 1994, 171(1):45-53.
22. Karner J., Meager A., Laan M., Maslovskaja J., Pihlap M., Remm A., Juronen E., Wolff A.S., Husebye E.S., Podkrajsek K.T., et al. Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice. Clin. Exp. Immunol. 2013, 171(3):263-272.
23. Gneiss C., Tripp P., Reichartseder F., Egg R., Ehling R., Lutterotti A., Khalil M., Kuenz B., Mayringer I., Reindl M., et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult. Scler. 2006, 12(6):731-737.
24. Files J.G., Gray J.L., Do L.T., Foley W.P., Gabe J.D., Nestaas E., Pungor E. A novel sensitive and selective bioassay for human type I interferons. J. Interferon Cytokine Res. 1998, 18(12):1019-1024.
25. Martins T.B., Rose J.W., Gardiner G.L., Kusukawa N., Husebye D., Hill H.R. Cell-based reporter gene assay for therapy-induced neutralizing antibodies to interferon-beta in multiple sclerosis. J. Interferon Cytokine Res. 2013, 33(2):52-57.
26. Bertolotto A., Sala A., Caldano M., Capobianco M., Malucchi S., Marnetto F., Gilli F. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J. Immunol. Methods 2007, 321(1-2):19-31.
27. Pachner A., Narayan K., Price N., Hurd M., Dail D. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol. Diagn. 2003, 7(1):17-25.
28. Deisenhammer F., Reindl M., Harvey J., Gasse T., Dilitz E., Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999, 52(6):1239-1243.
29. Gavasso S., Gjertsen B., Anderssen E., Myhr K., Vedeler C. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Mult. Scler. 2012, 18(8):1116-1124.
30. Meager A., Vincent A., Newsom-Davis J., Willcox N. Spontaneous neutralising antibodies to interferon-alpha and interleukin-12 in thymoma-associated autoimmune disease. Lancet 1997, 350(9091):1596-1597.
31. Suit B.E., Axelrod D., Moutsopoulos H.M., Decker J.L., Hooks J.J. Detection of anti-interferon antibodies in systemic lupus erythematosus. Clin. Exp. Rheumatol. 1983, 1(2):133-135.
32. Prummer O., Bunjes D., Wiesneth M., Hertenstein B., Arnold R., Porzsolt F., Heimpel H. Antibodies to interferon-alpha: a novel type of autoantibody occurring after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996, 17(4):617-623.
33. Ikeda Y., Toda G., Hashimoto N., Umeda N., Miyake K., Yamanaka M., Kurokowa K. Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis. Clin. Exp. Immunol. 1991, 85(1):80-84.
34. Rudick R.A., Simonian N.A., Alam J.A., Campion M., Scaramucci J.O., Jones W., Coats M.E., Goodkin D.E., Weinstock-Guttman B., Herndon R.M., et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998, 50(5):1266-1272.
35. Antonelli G., Giannelli G., Currenti M., Simeoni E., Del Vecchio S., Maggi F., Pistello M., Roffi L., Pastore G., Chemello L., et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. Clin. Exp. Immunol. 1996, 104(3):384-387.
36. Oftedal B.E., Kampe O., Meager A., Ahlgren K.M., Lobell A., Husebye E.S., Wolff A.S. Measuring autoantibodies against IL-17F and IL-22 in autoimmune polyendocrine syndrome type I by radioligand binding assay using fusion proteins. Scand. J. Immunol. 2011, 74(3):327-333.